Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignancy with both epithelial and sarcoma components, and high tumor metastasis potential. Case presentation: A 63-year-old male patient had a tumor in the right posterior mediastinum, and was eventually diagnosed with PSC and gingival metastasis. The patient underwent thoracoscopic right upper pneumonectomy with lymph node dissections, and the subsequent gingival biopsy revealed a metastatic PSC. The immunohistochemistry revealed that both PSC site tissues were positive for vimentin, CKAE1/AE3 and Ki-67. The patient received radiotherapy and chemotherapy after surgery, and deceased two months later due to systemic tumor metastases. Conclusion: PSC metastasis is variable, and leads to diagnostic dilemma or erroneous diagnosis. A differential diagnosis can help to distinguish it from gingival cancer.
Background
Pulmonary sarcomatoid carcinoma (PSC) is a very rare but aggressive type of non-small cell lung cancer (NSCLC). Clinically, PSC is characterized by tumor cells with histological, cytological, or molecular properties of both epithelial and mesenchymal tumors [1, 2] . PSC could be presented to have a large size with invasive tendency, early recurrence and systemic metastases. The incidence PSC has been reported to range between 0.1 and 0.4% in all diagnosed lung cancers [3] . In the present case report, the patient has a tumor in the right upper lobe of the lung, and suffered from swollen gums. During the hospitalization, the patient underwent surgery, and was histologically diagnosed with PSC, while the gingival biopsy revealed a metastatic PSC. Therefore, the present case is unique and worth reporting.
Case presentation
A 63-year-old patient with tobacco smoking history had cough and bloodstained sputum for a month. The computed tomography (CT) scan revealed an abnormal mass in the right posterior mediastinum. Subsequently, the patient was admitted to Jiangyin People's Hospital (Jiangsu, China) in October 2017 for the further evaluation and diagnosis of the abnormal mass. After the hospitalization, the patient's personal and medical records were found to be non-specific, the patient's performance status was good, and the general physical examination did not reveal any abnormalities. Importantly, the chest enhanced CT revealed a 2.8 × 2.5 cm mass in the right posterior mediastinum (Fig. 1) , and the abdominal CT ruled out any distant abnormal or metastasis lesions. Furthermore, the ultrasound gastroscope did not reveal any obvious abnormalities in the esophagus, while the bronchoscopy disclosed bloodstain in the posterior segment of the upper right lung, although the lavage, brush and sputum examinations were all negative. In addition, the patient complained of swelling in the right maxillary gingiva. The dental evaluation diagnosed the patient with periodontitis, and conservative treatment was given. Thereafter, the patient underwent the video-assisted thoracic surgery. During the procedure, the surgeon found that the posterior segment of the right upper lung lobe was adherent to the mediastinum, and that the tumor lesion was localized inside the lung. Thus, a Wedge resection of the right upper lung lobe was performed after separation of the adhesion. The frozen section diagnosis revealed a sarcomatoid carcinoma, resulting in the resection of the right upper lung lobe, together with the mediastinal lymph node dissections. The immunohistochemistry revealed that the sarcomatoid carcinoma was positive for vimentin, CKAE1/AE3 and Ki-67 (Fig. 2) .
During the patient's recovery from surgery, the patient's right maxillary gingival lesion gradually increased in size, and had bleeding. A tissue biopsy conducted by a dentist revealed a poorly differentiated tumor, and the immunostaining revealed that the tumor cells were positive for vimentin, CKAE1/AE3 and Ki-67 (Fig. 3) . The biopsy histology disclosed that the tumor lesion was identical to lung cancer, indicating a metastatic PSC. Thus, the patient underwent radiotherapy, followed by chemotherapy. During the chemotherapy, the magnetic resonance imaging (MRI) scan localized a 8 × 7 × 5.7 cm soft tissue mass in the right maxilla with unclear boundary, and local destruction of the maxilla and alveolar bone (Fig. 4) . Fifty days later, the patient stopped the chemotherapy due to poor systemic conditions, and was deceased as a result of multiple tumor metastases.
Discussion
The World Health Organization classifies PSC as a group of poorly differentiated NSCLCs with sarcoma or sarcoma-like differentiation [1] . The PSC subcategories could be pleomorphic carcinoma, pure spindle-cell carcinoma, pure giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. Recently, a study indicated that carcinosarcoma and pulmonary blastoma are histogenetically and morphologically distinct from the remaining tumors of this group, and its accurate subtyping and molecular and genetic classification could eventually lead to better therapy [4] . To date, the origin of the sarcoma component of PSC remains unclear, although previous studies have speculated that this is a clonal evolution [5, 6] , which induced PSC to have the histological characteristics of both epidermal and mesenchymal tumors. Using immunohistochemistry, the present PSC case was confirmed with the positive staining of epithelial markers (CK and EMA) and a mesenchymal marker (Vimentin), while Ki67 positivity confirmed the aggressiveness of PSC in tumor cell proliferation.
According to literature, the male-to-female ratio of PSC prevalence is approximately 4:1, and the average age at PSC diagnosis is 60 years old, while most male patients have a history of moderate-to-heavy tobacco consumption [7] . The common clinical symptoms include cough, expectoration, and chest congestion and pain [8] . PSC diagnosis mainly depends on tumor tissue histology and the immunohistochemical staining of epithelial and mesenchymal markers. However, a CT scan may also wall, and these are often accompanied by local or distant metastasis. (6) Calcification within a tumor mass is rare. Thus, the CT initially identifies the tumor, and the histology and immunohistochemistry would subsequently confirm the PSC in clinic. In addition, compared to other histologic subtypes of NSCLC, PSC is more aggressive with poor prognosis. For example, the average survival duration of PSC patients is only 13.3 months, which is lower than other types of NSCLC due to tumor early metastasis [9] . Furthermore, PSC also frequently metastasizes to the esophagus, colon, rectum and kidneys, in addition to the common metastatic sites of NSCLC [10] . In clinic, the main method of treatment for PSC is surgery, while radiotherapy and chemotherapy are the auxiliary methods, although most patients suffer from the advanced stage of disease and lose surgery opportunity for cure. Furthermore, two-thirds of patients are not sensitive to conventional chemotherapy. Previous studies [11, 12] have revealed that R+ resection, pathologic TNM status, and vascular emboli are all independent prognostic factors. However, PSC prognosis remains presently poor, regardless of whether the PSC diagnosis is early or late, and whether tumor metastasis is present [13] . Thus, novel treatment options are needed to cure PSC patients, or improve the long-term survival.
A previous study [14] reported that high invasiveness of PSC is associated with tumor cell epithelial-mesenchymal transition (EMT), which could cause the carcinoma component of PSC to transform into a sarcoma component. The EMT can also induce the PSC to be highly invasive and potentially metastasize. Molecularly, EMT mutation and programmed death-ligand 1 (PD-L1) overexpression are associated with a particular propensity for sarcomatoid carcinoma [15] . Thus, EMT and PD-L1 may play a role in PSC cell epithelial-mesenchymal transformation, especially the epithelial-mesenchymal transformation to sarcomatoid carcinoma. Hence, targeting the EMT and PD-L1 may be a future research direction for the treatment of PSC patients. Fig. 4 The nasopharyngeal MRI imaging during the chemotherapy. The MRI scan presents a 8 × 7 × 5.7 cm soft tissue mass localized at the right maxilla (red arrow), with an unclear boundary and local destruction of the maxilla and alveolar bone
